Amyloid-β (Aβ) aggregation inhibitor; blocks Aβ(1-42) aggregation and protects neuronal cell lines exposed to Aβ(1-42). Reduces Aβ oligomer-induced LTP and memory deficits in vivo.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 322.36. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.1 mL||15.51 mL||31.02 mL|
|5 mM||0.62 mL||3.1 mL||6.2 mL|
|10 mM||0.31 mL||1.55 mL||3.1 mL|
|50 mM||0.06 mL||0.31 mL||0.62 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Scopes et al (2012) Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity. Br.J.Pharmacol. 167 383 PMID: 22913627
If you know of a relevant reference for SEN 1269, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SEN1269 Amyloid-β (Aβ) aggregation inhibitors inhibits LTP memory Alzheimer's amyloidbeta amyloidb Amyloid Beta Peptides
Citations for SEN 1269
Citations are publications that use Tocris products.
Currently there are no citations for SEN 1269. Do you know of a great paper that uses SEN 1269 from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.